Trial Profile
KENya Single-dose HPV-vaccine Efficacy - The KEN-SHE Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; V 503 (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- Acronyms KEN-SHE
- 28 Jul 2022 Planned End Date changed from 15 Nov 2022 to 15 Feb 2024.
- 28 Jul 2022 Planned primary completion date changed from 15 Nov 2022 to 15 Feb 2024.
- 07 Feb 2020 Planned End Date changed from 31 Dec 2021 to 15 Nov 2022.